English (UK)
中文版- 1
- 2
Kintor Pharmaceuticals 
Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.
Mr. Mark Chen
BD DirectorKlUnited States Pharma 
Biologics Therapeutic development focUnited Statesed on oncology and IO. Looking for potential partnership opportunities for license in/out. www. KlUnited Statespharma.com
Laura Hong
PresidentKnightway Capital
Knightway Capital is a global investment firm focusing on med-tech, fin-tech, and legal-tech investments. We commit people, knowledge, and capital to empower revolutionary ideas and help exceptional entrepreneurs build enterprises contributing to the common good and long-term prosperity of society.
We are founded by a team of experienced professionals and executives with extensive industry expertise and backed by the most connected and influential investors and partners in the business ecosystem.
We are founded by a team of experienced professionals and executives with extensive industry expertise and backed by the most connected and influential investors and partners in the business ecosystem.
Cheng Charles
PartnerKymeris therapeutics Inc 
Kymeris has invented a revolutionary, live-cell based technology platform which delivers into the tumor micro-environment and activates there multiple therapeutic agents - including ligands, cytokines, and antibodies. Efficacy of anti-cancer action has been shown in 5 separate solid cancer indications with reduction in tumour size averaging 80% - but in many cases showing complete eradication. This game changing approach is of particular value to companies with proprietary molecules that are looking for safe and effective vectoring into tumors, and with whom we might partner.
Responsive Web Design powered by 